drugset / Trial / NCT07265739
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Phase 2
Not yet recruiting
27 enrolled
Massachusetts General Hospital
American Cancer Society, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.
Timeline
- Start
- 2026-08
- Primary completion
- 2027-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | 50 mg | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |